M

Monique P. C. Mulder

Leiden University Medical Center

ORCID: 0000-0001-5386-7132

Publishes on Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Protein Degradation and Inhibitors. 58 papers and 1.7k citations.

58Publications
1.7kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Ubiquitin ligation to F-box protein targets by SCF–RBR E3–E3 super-assembly
Cited by 199Open Access

Abstract E3 ligases are typically classified by hallmark domains such as RING and RBR, which are thought to specify unique catalytic mechanisms of ubiquitin transfer to recruited substrates 1,2 . However, rather than functioning individually, many neddylated cullin–RING E3 ligases (CRLs) and RBR-type E3 ligases in the ARIH family—which together account for nearly half of all ubiquitin ligases in humans—form E3–E3 super-assemblies 3–7 . Here, by studying CRLs in the SKP1–CUL1–F-box (SCF) family, we show how neddylated SCF ligases and ARIH1 (an RBR-type E3 ligase) co-evolved to ubiquitylate diverse substrates presented on various F-box proteins. We developed activity-based chemical probes that enabled cryo-electron microscopy visualization of steps in E3–E3 ubiquitylation, initiating with ubiquitin linked to the E2 enzyme UBE2L3, then transferred to the catalytic cysteine of ARIH1, and culminating in ubiquitin linkage to a substrate bound to the SCF E3 ligase. The E3–E3 mechanism places the ubiquitin-linked active site of ARIH1 adjacent to substrates bound to F-box proteins (for example, substrates with folded structures or limited length) that are incompatible with previously described conventional RING E3-only mechanisms. The versatile E3–E3 super-assembly may therefore underlie widespread ubiquitylation.

A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations
Elma Mons, Sander Roet, Robbert Q. Kim et al.|Current Protocols|2022
Cited by 111Open Access

Abstract Covalent inhibition has become more accepted in the past two decades, as illustrated by the clinical approval of several irreversible inhibitors designed to covalently modify their target. Elucidation of the structure‐activity relationship and potency of such inhibitors requires a detailed kinetic evaluation. Here, we elucidate the relationship between the experimental read‐out and the underlying inhibitor binding kinetics. Interactive kinetic simulation scripts are employed to highlight the effects of in vitro enzyme activity assay conditions and inhibitor binding mode, thereby showcasing which assumptions and corrections are crucial. Four stepwise protocols to assess the biochemical potency of (ir)reversible covalent enzyme inhibitors targeting a nucleophilic active site residue are included, with accompanying data analysis tailored to the covalent binding mode. Together, this will serve as a guide to make an educated decision regarding the most suitable method to assess covalent inhibition potency. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol I : Progress curve analysis of substrate association competition Basic Data Analysis Protocol 1A : Two‐step irreversible covalent inhibition Basic Data Analysis Protocol 1B : One‐step irreversible covalent inhibition Basic Data Analysis Protocol 1C : Two‐step reversible covalent inhibition Basic Data Analysis Protocol 1D : Two‐step irreversible covalent inhibition with substrate depletion Basic Protocol II : Incubation time–dependent potency IC 50 ( t ) Basic Data Analysis Protocol 2 : Two‐step irreversible covalent inhibition Basic Protocol III : Preincubation time–dependent inhibition without dilution Basic Data Analysis Protocol 3 : Preincubation time–dependent inhibition without dilution Basic Data Analysis Protocol 3Ai : Two‐step irreversible covalent inhibition Alternative Data Analysis Protocol 3Aii : Two‐step irreversible covalent inhibition Basic Data Analysis Protocol 3Bi : One‐step irreversible covalent inhibition Alternative Data Analysis Protocol 3Bii : One‐step irreversible covalent inhibition Basic Data Analysis Protocol 3C : Two‐step reversible covalent inhibition Basic Protocol IV : Preincubation time–dependent inhibition with dilution/competition Basic Data Analysis Protocol 4 : Preincubation time–dependent inhibition with dilution Basic Data Analysis Protocol 4Ai : Two‐step irreversible covalent inhibition Alternative Data Analysis Protocol 4Aii : Two‐step irreversible covalent inhibition Basic Data Analysis Protocol 4Bi : One‐step irreversible covalent inhibition Alternative Data Analysis Protocol 4Bii : One‐step irreversible covalent inhibition

A Native Chemical Ligation Handle that Enables the Synthesis of Advanced Activity‐Based Probes: Diubiquitin as a Case Study
Cited by 96Open Access

We present the development of a native chemical ligation handle that also functions as a masked electrophile that can be liberated during synthesis when required. This handle can thus be used for the synthesis of complex activity-based probes. We describe the use of this handle in the generation of linkage-specific activity-based deubiquitylating enzyme probes that contain substrate context and closely mimic the native ubiquitin isopeptide linkage. We have generated activity-based probes based on all seven isopeptide-linked diubiquitin topoisomers and demonstrated their structural integrity and ability to label DUBs in a linkage-specific manner.